Items tagged with Scientific research
WHO calls for increased transparency in medical research (post)
14 APRIL 2015 | GENEVA - WHO today issued a public statement calling for the disclosure of results from clinical trials for medical products, whatever the result. The move aims to ensure that decisions related to the safety and efficacy of vaccines, drugs and medical devices for use by populations are supported by the best available evidence.
Novartis receives US Patent and Trademark Office 2015 ‘Patents for Humanity’ award (post)
Novartis recognized for licensing agreement to provide promising drug candidates to the Global Alliance for TB Drug Development
Award recognizes ‘game changing’ innovations that have the potential to solve long-standing challenges in medicine, nutrition, sanitation, energy and living standards
Fighting tuberculosis using the body's natural anti-microbial processes (post)
New Rochelle, NY, April 15, 2015—A new approach to combatting tuberculosis would take advantage of a complex, natural process called autophagy that the human body uses to recycle nutrients, remove damaged cell components, eliminate invading bacteria, and respond to inflammation. In addition to its potential as a novel therapeutic strategy, autophagy is the focus of increasing research to understand the role it may have in a range of diseases including heart disease, diabetes, and age-related neurodegenerative disorders such as Alzheimer’s disease, as discussed in a series of in-depth articles that comprise the special issue “Autophagy in Disease” of DNA and Cell Biology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The issue is available free on the DNA and Cell Biology website until May 15, 2014.
US-South Africa programme funds new TB, HIV research (post)
[CAPE TOWN] A five-year collaborative research programme to promote HIV/AIDS and tuberculosis (TB) research in South Africa has announced new first-year grants worth US$8 million.
Host for new TB clinical trial data-sharing platform selected (post)
TUCSON, Ariz., April 29, 2015 — The non-profit Critical Path Institute has been selected to host a new tuberculosis (TB) clinical trial data sharing platform. The initiative will start by creating a common database from three Phase III clinical trials earlier supported by the Special Programme for Research and Training in Tropical Diseases (TDR), the TB Alliance and St. George’s, University of London.
Lakewood-Amedex announces its novel bisphospocin® class of antimicrobials kills multidrug-resistant tuberculosis (MDR-TB) strains in fifteen minutes (post)
SARASOTA, Fla., May 19, 2015 -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, the bacteria responsible for the chronic lung infection tuberculosis. Approximately one-third of the world's population is infected by this bacteria, which is increasingly becoming resistant to the current five-drug cocktail used to treat these infections. This issue is sparking serious concern in world health organizations and medical communities as they no longer have an effective cure for many of these patients.
Immunity enzyme defends against tuberculosis infection (post)
DALLAS – June 2, 2015 – A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually.
How the tuberculosis bacterium tricks the immune system (post)
03.06.15 - Scientists at EPFL have discovered how the tuberculosis bacterium can trick the patient’s immune cells to lower their defenses.
New hope in the fight against tuberculosis (post)
Scientists from the HIPS and the HZI discover a new target for the fight against multi-resistant mycobacteria, from a rejuvenated antibiotic series
Massachusetts General Hospital launches phase II trial of BCG vaccine to reverse type 1 diabetes (post)
07/Jun/2015 - A phase II clinical trial testing the ability of the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes has received approval from the U.S. Food and Drug Administration (FDA). The approval of this trial, which will shortly begin enrolling qualified patients, was announced today at the 75th Scientific Sessions of the American Diabetes Association (ADA) by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobiology Laboratory and principal investigator of the study.
Page 9 of 74 · Total posts: 0
←First 8 9 10 Last→